Journals / Literatür Eczacılık Bilimleri Dergisi / 2018 / Cilt: 7 - Sayı: 3

A Review on Doxurubicin Related Genotoxic and Protective Effects of Phytochemicals

Doksorubisine Bağlı Genotoksik Etkiler ve Fitokimyasalların Koruyucu Etkilerinin Değerlendirilmesi

Pages
237–250
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

In this review, the information on the mechanism of action of doxorubicin, toxicity and the protective effects of phytochemicals for reducing this toxicity are given.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Doxorubicin is an anthracycline antibiotic that possesses broad spectrum antineoplastic activity and is one of the most widely used chemotherapeutic agents.
📊
Key Findings & Data:Doxorubicin is preferred for first-line treatment in both child and adult patients.
💡
Conclusion & Impact:In this review, the information on the mechanism of action of doxorubicin, toxicity and the protective effects of phytochemicals for reducing this toxicity are given.
🔬Design:Review & Systematic Survey
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Doxorubicin is an anthracycline antibiotic that possesses broad spectrum antineoplastic activity and is one of the most widely used chemotherapeutic agents. Doxorubicin is preferred for first-line treatment in both child and adult patients. It is used in various types of cancer such as breast, stomach, thyroid, prostate, testis, over, cervix, soft tissue and bone sarcoma. Like other chemotherapeutic agents, the side effects of doxorubicin are often linked to cytotoxicity against non-selective, normally proliferating cells. In addition, cardiotoxicity and bone marrow suppression limit the use of this drug. Furthermore, during or after chemotherapy treatment, malignant secondary tumors different from primary tumors can develop due to treatment. Free radical production is regarded as the primary mechanism responsible for the genotoxicity of doxorubicin. It causes DNA damage and effects DNA replication resulting in gene mutations, and secondary malignant neoplasms. Phytochemicals play a role in the protection against oxidative damage, the modulation of DNA repair genes and genes controlling cell cycle, the induction of apoptosis, the inhibition of angiogenesis and the regulation of the invasion and spread of tumor cells and epigenetic changes. Many natural compounds with antioxidant properties promise to prevent or reduce the toxic effects of doxorubicin without decreasing its anticancer effect. In this review, the information on the mechanism of action of doxorubicin, toxicity and the protective effects of phytochemicals for reducing this toxicity are given.

Özet

Antrasiklin sınıfında yer alan geniş spektrumlu bir antineoplastik ajan olan doksorubisin en yaygın kullanılan kemoterapötik ajanlardan biridir. Hem çocuk hem erişkin hastalarda birinci basamak tedavide tercih edilmekte ve meme, mide, tiroid, prostat, testis, over, serviks, yumuşak doku ve kemik sarkomları gibi çeşitli kanser türlerinde kullanılmaktadır. Doksorubisinin diğer kemoterapötik ajanlar gibi yan etkileri çoğunlukla normal hücrelere karşı selektif olmayan şekilde sitotoksik etki göstermesiyle bağlantılıdır. Bununla birlikte, kardiyotoksisite ve kemik iliği baskılayıcı etkisi bu ilacın kullanımını kısıtlamaktadır. Ayrıca, kemoterapi tedavisi sırasında veya sonrasında, birincil tümörlerden farklı olan kötü huylu ikincil tümörlerin tedaviye bağlı olarak gelişebilmesi diğer önemli bir sorunu oluşturmaktadır. Serbest radikal üretimi, doksorubisinin genotoksik etkisinden sorumlu primer mekanizma olarak kabul edilmekte olup, DNA hasarına neden olması ve DNA replikasyonunu etkilemesiyle mutasyonlara ve ikincil kötü huylu tümörlerin gelişmesine sebep olmaktadır. Fitokimyasallar oksidatif hasara karşı korumada, DNA tamir genlerinin ve hücre siklusunu kontrol eden genlerin modülasyonunda, apoptozun uyarılmasında, anjiogenezin engellenmesinde ve tümör hücresinin invazyonunun ve yayılmasının düzenlenmesinde ve epigenetik değişikliklerde rol oynamaktadır. Antioksidan özelliklere sahip birçok doğal bileşik, doksorubisinin antitümör etkisini azaltmadan, toksik etkilerin önlenmesinde veya azaltılmasında ümit vadetmektedir. Bu çalışmada; doksorubisinin etki mekanizmaları, toksisitesi ve bu toksisiteyi azaltmaya yönelik fitokimyasalların koruyucu etkileri hakkında bilgi verilmesi amaçlanmıştır.

🔖

Cite This Article

HELVACIOĞLU, S., CHAREHSAZ, M., AYDIN, A. (2018). A Review on Doxurubicin Related Genotoxic and Protective Effects of Phytochemicals. Literatür Eczacılık Bilimleri Dergisi, Cilt: 7 - Sayı: 3, 237–250. https://ajindex.com/articles/274620

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (16)

  1. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in Globocan 2012. Int J Cancer 2015;136(5):E359-86
  2. Temel MK. [The development of cytotoxic chemotherapeutics in the twentieth century]. Türk Onkoloji Dergisi 2015;30(2):96-108
  3. Türker A, Kayaalp SO. [Principles of cancer chemotherapy and antineoplastic drugs]. Kayaalp SO, editör. Rasyonel Tedavi Yönünden Tıbbi Farmakoloji
  4. Baskı. Ankara: Hacettepe-Taş; 2005. p.317-41
  5. Corrie PG. Cytotoxic chemotherapy: clinical aspects. Medicine 2008;36(1):24-8
  6. Grynkiewicz G, Szeja W. Synthesis of the sugar moieties. In: Krohn K, ed. Anthracycline Chemistry and Biology I: Biological Occurence and Biosynthesis, Synthesis and Chemistry. Berlin: Springer; 2008. p.249-84
  7. Minotti G, Menna P, Salvatorelli E, Cairo G, Gianni L. Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol Rev 2004;56(2):185-229
  8. Robert J, Gianni L. Pharmacokinetics and metabolism of anthracyclines. Cancer Surv 1993;(17):219-52
  9. Woo MH, Evans WE, Relling MV. Pharmacokinetic and pharmacodynamic considerations. In: Pui CH, ed. Childhood Leukemias. 1st ed. Cambridge: Cambridge University; 1999. p.275-6
  10. Mordente A, Meucci E, Martorana GE, Giardina B, Minotti G. Human heart cytosolic reductases and anthracycline cardiotoxicity. IUBMB Life 2001;52(1-2):83-8
  11. Cortés-Funes H, Coronado C. Role of anthracyclines in the era of targeted therapy. Cardiovasc Toxicol 2007;7(2):56-60
  12. Wang S, Konorev EA, Kotamraju S, Joseph J, Kalivendi S, Kalyanaraman B. Doxorubicin induces apoptosis in normal and tumor cells via distinctly different mechanisms intermediacy of H(2)O(2)- and p53-dependent pathways. J Biol Chem 2004;279(24):25535-43
  13. Chu E, Sartorelli AC. Cancer chemotherapy. In: Katzung BG, ed. Basic & Clinical Pharmacology. 12th ed. New York: McGraw-Hill Medical Publishing Division; 2001. p.965
  14. Anderson RD, Berger NA. International Commission for Protection Against Environmental Mutagenes and Carcinogens. Mutagenicity and carcinogenicity of topoisomerase-interactive agents. Mutat Res 1994;309(1):109- 42
  15. Agapito MT, Antolín Y, del Brio MT, LόpezBurillo S, Pablos MI, Recio JM. Protective effect of melatonin against adriamycin toxicity in the rat. J Pineal Res 2001;31(1):23-30
  16. Karagoz B, Suleymanoglu S, Uzun G, Bilgi O, Aydinoz S, Haholu A, et al. [H